Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, Y.
Right arrow Articles by Gordon, G. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, Y.
Right arrow Articles by Gordon, G. B.
Mol Cancer Ther. 2004;3:885-893
© 2004 American Association for Cancer Research

Minireview

A strategy for cancer prevention: Stimulation of the Nrf2-ARE signaling pathway

Yuesheng Zhang1 and Gary B. Gordon2

1 Department of Chemoprevention, Roswell Park Cancer Institute, Buffalo, New York and 2 Abbott Laboratories, Abbott Park, Illinois

Requests for reprints: Yuesheng Zhang, Department of Chemoprevention, Roswell Park Cancer Institute, Science 711, Elm and Carlton Streets, Buffalo, NY 14263. Phone: 716-845-3097; Fax: 716-845-1144. E-mail: yuesheng.zhang{at}roswellpark.org

Many genes, with products involved in the protection of cells against carcinogens, oxidants, and other toxic chemicals, are under the transcriptional control of a simple DNA regulatory element [i.e., the antioxidant response element (ARE)]. One or more functional AREs have been confirmed or are believed to exist in the upstream region of many anticarcinogenic/antioxidant genes and have been shown to mediate the coordinate transcriptional up-regulation of these genes by many chemical agents [i.e., the ARE-mediated inducers]. There is strong evidence that increased expression of ARE-regulated genes inhibits cancer development. The signaling system leading to ARE activation has been partly elucidated, and nuclear factor erythroid 2–related factor 2 (Nrf2) has been identified as the key transcriptional factor that serves to transmit the inducer signal to ARE. It is now known that nuclear factor erythroid 2–related factor 2, which is normally sequestered in the cytoplasm by Kelch-like ECH-associated protein 1, dissociates from Kelch-like ECH-associated protein 1 on exposure to ARE-mediated inducers, translocates to the nucleus, complexes with other nuclear factors, and binds to ARE. Rapid and simple assays have been devised to identify chemical agents that can stimulate this signaling pathway. Moreover, many ARE-mediated inducers have been identified, and several of them have shown promising cancer preventive activity.


Grant support: National Cancer Institute grants CA80962 and CA100623 (Y. Zhang).

Received 3/ 5/04; revised 4/26/04; accepted 5/ 5/04.




This article has been cited by other articles:


Home page
Ann. N. Y. Acad. Sci.Home page
T. M. BUETLER, H. LATADO, A. BAUMEYER, and T. DELATOUR
Dicarbonyls Stimulate Cellular Protection Systems in Primary Rat Hepatocytes and Show Anti-inflammatory Properties
Ann. N.Y. Acad. Sci., April 1, 2008; 1126(1): 113 - 117.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. B. Sibhatu, P. K. Smitherman, A. J. Townsend, and C. S. Morrow
Expression of MRP1 and GSTP1-1 modulate the acute cellular response to treatment with the chemopreventive isothiocyanate, sulforaphane
Carcinogenesis, April 1, 2008; 29(4): 807 - 815.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Hinoi, S. Fujimori, L. Wang, H. Hojo, K. Uno, and Y. Yoneda
Nrf2 Negatively Regulates Osteoblast Differentiation via Interfering with Runx2-dependent Transcriptional Activation
J. Biol. Chem., June 30, 2006; 281(26): 18015 - 18024.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
C.-T. Yeh and G.-C. Yen
Involvement of p38 MAPK and Nrf2 in phenolic acid-induced P-form phenol sulfotransferase expression in human hepatoma HepG2 cells
Carcinogenesis, May 1, 2006; 27(5): 1008 - 1017.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
M. Marin-Kuan, S. Nestler, C. Verguet, C. Bezencon, D. Piguet, R. Mansourian, J. Holzwarth, M. Grigorov, T. Delatour, P. Mantle, et al.
A Toxicogenomics Approach to Identify New Plausible Epigenetic Mechanisms of Ochratoxin A Carcinogenicity in Rat
Toxicol. Sci., January 1, 2006; 89(1): 120 - 134.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Liby, T. Hock, M. M. Yore, N. Suh, A. E. Place, R. Risingsong, C. R. Williams, D. B. Royce, T. Honda, Y. Honda, et al.
The Synthetic Triterpenoids, CDDO and CDDO-Imidazolide, Are Potent Inducers of Heme Oxygenase-1 and Nrf2/ARE Signaling
Cancer Res., June 1, 2005; 65(11): 4789 - 4798.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. J. Calkins, R. J. Jakel, D. A. Johnson, K. Chan, Y. W. Kan, and J. A. Johnson
Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription
PNAS, January 4, 2005; 102(1): 244 - 249.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2004 by the American Association for Cancer Research.